NCT06614205View on ClinicalTrials.gov

Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

February 25, 2025

Conditions
Meningioma of Brain
Interventions
DIAGNOSTIC_TEST

tumoral dosimetry by scintigraphy

The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment

Trial Locations (2)

54511

CHRU de NANCY, Vandœuvre-lès-Nancy

Nuclear medicine Department CHRU de NANCY, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT06614205 - Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma | Biotech Hunter | Biotech Hunter